STARGARDT DISEASE THERAPEUTICS MARKET ANALYSIS

Stargardt Disease Therapeuticss Market, By Drug Type (Emixustat, LBS-008, others (Gildeuretinol), By Age Group (Children (Below 17 Years) and Adult (Above 17 Years)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Sep 2023
Code : CMI1314
Pages :167
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Stargardt Disease Therapeutics Market: Key Developments

In October 2022, ATP, a life sciences venture firm, is the most recent startup to make its debut with a novel approach to genetic editing. With US$ 50 million in funding, U.S.-based Ascidian Therapeutics claims that its RNA “exon editing” approach could match the durability of gene therapy while avoiding some of the risks that come with editing DNA. The platform is designed to correct for mutations in exons,the regions of DNA that contain information needed to make proteins